Welcome to our dedicated page for Quidel news (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on Quidel stock.
Overview
QuidelOrtho Corporation (symbol: QDEL) is an American diagnostic healthcare manufacturer that specializes in rapid diagnostic testing solutions. The company is renowned for its innovative approaches in rapid diagnostic testing, immunoassay, and molecular diagnostics, offering products that enable clinicians and laboratories worldwide to quickly and accurately diagnose medical conditions.
Core Business Areas
QuidelOrtho develops, manufactures, and markets a wide range of diagnostic products across several key segments. Its product portfolio includes:
- Immunoassay Testing: Designed to detect a variety of biological markers, these tests help in early and rapid disease detection.
- Molecular Diagnostics: Utilizing nucleic acid amplification, these solutions provide high sensitivity and specificity in detecting pathogens and genetic markers.
- Clinical Chemistry: The company leverages advanced technology to perform biochemical assays that aid clinical decision-making.
- Transfusion Medicine: This segment supports safe blood management and compatibility testing in healthcare settings.
Global Footprint
Operating on a global scale, QuidelOrtho maintains a significant presence in North America while extending its reach to EMEA, China, and other international markets. This geographic diversity allows the company to adapt its product offerings to various regulatory environments and healthcare needs around the world, reinforcing its commitment to improving patient care globally.
Market Position and Competitive Landscape
In the highly competitive diagnostic healthcare industry, QuidelOrtho distinguishes itself through its focus on rapid, reliable testing solutions that meet the evolving needs of modern clinical practice. The company faces competitive pressures from other diagnostic manufacturers; however, its continued emphasis on research, technological innovation, and quality manufacturing processes has carved out a robust position in the market. Its strategy is built on addressing the challenges of timely diagnosis, which is critical for effective treatment and patient management.
Value Proposition and Business Model
The core value of QuidelOrtho lies in its ability to deliver quick, accurate, and reliable diagnostic results. This capability is essential for the effective treatment of patients, particularly in settings where speed is of the essence. The company generates revenue primarily through the direct sale of its diagnostic products to hospitals, clinics, and laboratories. Its business model is supported by a strong emphasis on technological innovation, quality assurance, and compliance with industry and regulatory standards, ensuring that its products remain at the forefront in the competitive diagnostic landscape.
Expertise and Innovation
QuidelOrtho exemplifies the integration of technology and medicine, offering diagnostic solutions that empower healthcare professionals to make informed decisions swiftly. By continuously investing in research and development, the company not only meets current market demands but also anticipates the needs of the evolving diagnostic market. The emphasis on product quality and technological sophistication underscores the company’s credibility and authority within the diagnostic sector.
Summary
Overall, QuidelOrtho Corporation represents a comprehensive approach to diagnostic healthcare. Its diversified product portfolio, global reach, and commitment to rapid and precise diagnostic testing underscore its significance as a major player in the industry. The company's focus on reinvigorating traditional diagnostic methods with innovative technologies continues to set it apart, establishing a strong foundation built on expertise, quality, and a deep understanding of the diagnostic landscape.
QuidelOrtho (Nasdaq: QDEL) has launched the Results Manager™ System, an advanced informatics solution designed for laboratories in community hospitals and point-of-care settings. The system offers key features including:
- Real-time quality monitoring for instruments and assays
- Operational efficiency through auto-verification and simplified rule-writing
- Seamless connectivity with multiple instruments
- Enhanced clinical decision-making capabilities
- Cost-effective deployment with easy installation
The system addresses critical challenges such as rising test volumes, staffing shortages, and increasing complexity while maintaining focus on patient care. Early trial users, including Lab Manager Steve Mulliner from MB Healthcare Services , reported positive feedback on the system's intuitive interface and efficiency improvements. QuidelOrtho is now launching the Results Manager system worldwide, with availability varying by country.
QuidelOrtho (NASDAQ: QDEL), a global provider of innovative in-vitro diagnostic technologies, has announced its participation in the 46th Annual Raymond James Institutional Investor Conference. The company's management team will deliver a presentation on Wednesday, March 5, 2025, at 8:40 a.m. ET / 5:40 a.m. PT.
Investors and interested parties can access both the live webcast and replay of the presentation through the 'Events & Presentations' section on QuidelOrtho's Investor Relations website at https://ir.quidelortho.com. The company specializes in diagnostic technologies for point-of-care settings, clinical labs, and transfusion medicine.
QuidelOrtho (QDEL) reported Q4 2024 revenue of $708 million, down from $743 million year-over-year, primarily due to lower COVID-19 and influenza revenue. Q4 non-respiratory revenue was $565 million, while respiratory revenue decreased 18% to $143 million.
Full-year 2024 revenue reached $2.8 billion, compared to $3.0 billion in 2023. The company reported a GAAP net loss of $2.03 billion for 2024, including a $1.82 billion non-cash goodwill impairment charge. Adjusted EBITDA was $543 million with a 19.5% margin, down from $723 million and 24% margin in 2023.
Looking ahead, QuidelOrtho issued 2025 guidance projecting revenue between $2.60-$2.81 billion, adjusted EBITDA of $575-$615 million, and adjusted EBITDA margin of 22%. The company expects a $55 million negative impact from foreign currency exchange based on January 2025 rates.
QuidelOrtho (NASDAQ: QDEL) has announced preliminary unaudited revenue for Q4 2024, with expected total reported revenues ranging between $702 million to $707 million, aligning with previously announced guidance. The breakdown includes:
- Non-respiratory revenue: $561-563 million
- Respiratory revenue: $141-143 million
The company had a transformative 2024, focusing on high-growth opportunities, leadership realignment, and implementing cost-saving measures. QuidelOrtho plans to release complete Q4 and full-year 2024 financial results on February 12, 2025, followed by a conference call at 2:00 p.m. PT / 5:00 p.m. ET.
QuidelOrtho (QDEL), a global provider of in-vitro diagnostic technologies, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team will deliver a presentation on Monday, January 13, 2025, at 7:30 a.m. PST / 10:30 a.m. EST. Investors and interested parties can access both the live webcast and replay through the 'Events & Presentations' section on QuidelOrtho's investor relations website.
QuidelOrtho (QDEL) has announced the pricing of a secondary offering where Carlyle Partners VI Cayman Holdings will sell 8,260,183 shares of common stock. Goldman Sachs & Co. is serving as the sole underwriter for the offering, which is expected to close on November 21, 2024. QuidelOrtho will not receive any proceeds from this transaction as all proceeds will go to the selling stockholder. The offering is being conducted through an effective shelf registration statement filed with the SEC.
QuidelOrtho (QDEL) announced a secondary offering where Carlyle Partners VI Cayman Holdings will sell 8,260,183 shares of common stock. The last reported stock price was $38.58 per share on November 19, 2024. Goldman Sachs & Co. is the sole underwriter. Following the offering, Carlyle will exit its position entirely, terminating their Principal Stockholders Agreement and losing board nomination rights. QuidelOrtho will not receive any proceeds from this offering as all proceeds go to the selling stockholder.
QuidelOrtho reported its Q3 2024 financial results, highlighting a total revenue of $727 million, down from $744 million the previous year, mainly due to higher COVID-19 and influenza revenues in the prior period. GAAP net loss was $20 million compared to $13 million last year, with a GAAP diluted loss per share of ($0.30) versus ($0.19). GAAP operating income was $15 million, down from $26 million, and GAAP operating margin was 2%, compared to 4% previously. Adjusted EPS was $0.85, slightly down from $0.90. Adjusted EBITDA was $171 million, up from $169 million, with a margin of 23.5% compared to 22.7%.
The company reinstated 2024 financial guidance, projecting total revenues of $2.75-$2.80 billion, adjusted EBITDA of $530-$550 million, and adjusted EPS of $1.69-$1.91. QuidelOrtho also emphasized ongoing cost-saving initiatives and leadership enhancements to drive future growth.
QuidelOrtho (Nasdaq: QDEL), a global provider of in vitro diagnostic technologies, has announced its participation in three major investor conferences. The company will engage in fireside chats at the UBS Global Healthcare Conference on November 12, 2024, at 2:00 p.m. ET in Rancho Palos Verdes, the Citi 2024 Global Healthcare Conference on December 4, 2024, at 1:00 p.m. ET in Miami, and the Evercore ISI 7th Annual HealthConX Conference on December 5, 2024, at 10:00 a.m. ET in Coral Gables. Live webcasts and replays will be available through QuidelOrtho's investor relations website.
QuidelOrtho (Nasdaq: QDEL), a global provider of innovative in vitro diagnostic technologies, has announced that it will report its financial results for the third quarter of 2024 on Thursday, November 7, 2024, after the market close. The company will hold a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results.
Interested parties can access the call through the 'Events & Presentations' section of the company's Investor Relations webpage. Presentation materials will be posted at the time of the call. Those unable to access the webcast can join via phone by dialing 833-470-1428 (domestic) or +1 929-526-1599 (international) with Conference ID number 117739. A replay of the call will be available on the company's website shortly after the event.
FAQ
What is the current stock price of Quidel (QDEL)?
What is the market cap of Quidel (QDEL)?
What is the core business of QuidelOrtho Corporation?
Which healthcare segments does QuidelOrtho serve?
How does QuidelOrtho generate its revenue?
What differentiates QuidelOrtho from other diagnostic manufacturers?
Where does QuidelOrtho have a global presence?
What role does innovation play in QuidelOrtho's business model?
How does QuidelOrtho contribute to clinical decision-making?
What are some common applications of QuidelOrtho's diagnostic tests?
